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Abstract 9 
Efflux pumps are membrane proteins which contribute to multi-drug resistance. In 10 
Gram-negative bacteria, some of these pumps form complex tripartite assemblies in 11 
association with an outer membrane channel and a periplasmic fusion protein. These 12 
tripartite machineries span both membranes and the periplasmic space, and they 13 
extrude from the bacterium chemically diverse toxic substrates. In this chapter, we 14 
summarise current understanding of the structural architecture, functionality, and 15 
regulation of tripartite multi-drug efflux assemblies. 16 
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Introduction 21 
The tripartite efflux pumps of Gram-negative bacteria are complex molecular 22 
assemblies that expel antibiotics and other toxic agents from the cell. The capacity of tripartite 23 
systems to transport a variety of chemically diverse antibiotics and other bactericidal substrates 24 
contributes to multi-drug resistance of Gram-negative bacteria and thus to the worldwide 25 
emerging threat of untreatable infections (overview in [1]). 26 
One well-studied representative of tripartite efflux pumps is the AcrA-AcrB-TolC 27 
(hereafter AcrAB-TolC) assembly of Escherichia coli. The pump has become a paradigm 28 
system to understand the structure and activities of homologous tripartite assemblies found in 29 
phylogenetically diverse bacterial species, including those associated with clinical severity in 30 
	 2 
drug resistant infections [2-4]. Like numerous other tripartite systems, the AcrAB-TolC pump 31 
spans the two lipid bilayers and an interstitial peptidoglycan network that together comprise 32 
the cell envelope of the Gram-negative species. A nanomachine driven by proton-motive force, 33 
AcrAB-TolC has been shown to transport antibiotics and a range of chemically diverse 34 
bactericidal compounds [5, 6] [7] [8, 9]. Other tripartite systems drive efflux of more specific 35 
compounds; for example, the CusA-CusB-CusC pump is involved in the efflux of toxic copper 36 
and silver ions [10, 11].  37 
The energy-transducing component of AcrAB-TolC system is the trimeric inner 38 
membrane protein AcrB, which is a member of the Resistance-Nodulation-Cell division (RND) 39 
superfamily. Tripartite assemblies can also form based on inner membrane transporters from 40 
the major facilitator superfamily (MFS) and ATP-binding cassette (ABC) groups. A schematic 41 
overview of different tripartite systems is displayed in Figure 1A-D. 42 
 43 
 44 
Fig. 1. Schematic overview of the architecture of different tripartite systems. (A) The 45 
AcrAB-TolC tripartite assembly expels toxic substances utilizing the proton-motive force as 46 
energy source by AcrB. Substrates are exported in exchange for the uptake of protons. (B) 47 
MacAB-TolC drive transport by hydrolysis of ATP. (C) The type I secretion system HlyDB-48 
	 3 
TolC shares some features with the MacAB-TolC system, although the intracellular ATPase 49 
domain is elaborated with additional domains. (D) The EmrAB-TolC tripartite system. EmrB 50 
is a member of the major facilitator superfamily of membrane transporters and utilises proton-51 
motive force for extrusion of toxic substrates. The structure of EmrB and subunit stoichiometry 52 
of the EmrAB-TolC tripartite system are unknown. EmrA was shown to form both dimers and 53 
trimers [12] and electron microscopy data of reconstituted EmrAB suggests a putative ‘dimer 54 
of dimers’ assembly [13]. Arrows indicate energy-coupling (brown) and the proposed 55 
schematic substrate transport pathways (black). LPS abbreviates lipopolysaccharide, and the 56 
peptidoglycan is composed of repeating units of the disaccharide N-acetyl glucosamine-N-57 
acetyl muramic acid.  58 
 59 
Tripartite systems play numerous physiological roles beyond capacity for antibiotic 60 
efflux, as might be anticipated from their ancient evolutionary history. For example, some of 61 
the pumps can transport quorum signalling molecules [14-17] and virulence factors [18-27], or 62 
act as a “metabolic relief valve” to expel products that become hazardous due to imbalanced 63 
metabolism [28].  64 
Atomistic structures of the individual components and the full assemblies have been 65 
elucidated for the RND and ATP-based pumps, and we describe here the key features of the 66 
quaternary organisation and the communication between subunits during the transport process. 67 
 68 
The components of tripartite efflux pumps 69 
Three protein components form the canonical tripartite assembly. The individual 70 
component structures of the AcrAB-TolC tripartite pump assembly, including the auxiliary 71 
factor AcrZ, are displayed in Figure 2. We present each of the components in turn.  72 
	 4 
The inner membrane protein component (IMP) of the pump assembly, i.e. the 73 
transporter, transduces energy to drive the active efflux of substrates through the tripartite 74 
assembly. The inner membrane ATP-binding cassette transporters such as MacB of the 75 
MacAB-TolC tripartite system couple transport processes with the binding and hydrolysis of 76 
ATP. AcrB and other RND transporters harness the energy from the controlled flow of protons 77 
to promote conformational changes that enable binding and movement of substrates into the 78 
channel of tripartite assembly. Structures of AcrB [29] in apo and ligand-bound states have 79 
been solved using X-ray crystallography and provide insight into the conformational changes 80 
associated with substrate binding and the pathway for conducting protons. AcrB has a peptide 81 
partner AcrZ that affects its transport activity for a subset of substrates. AcrZ is a small protein 82 
of 49 amino acids that makes an extensive interface with the AcrB transmembrane domain 83 
[30].  84 
TolC is a representative of the outer membrane protein (OMP) component of tripartite 85 
pump (Figure 2A, B). Crystal structures of TolC from numerous species, including E. coli and 86 
the homologue VceC from Vibrio cholerae, reveal an architecture of extended a-helices that 87 
bundle into coiled-coils and pinch together to form a semi-porous seal at the periplasmic end 88 
of the trimer. At the time that the first crystal structure of the isolated TolC was elucidated, it 89 
seemed clear that the closed periplasmic end must be dilated at some stage of the transport 90 
process in order to accommodate even the smallest of the known transport substrates. The 91 
process of TolC opening has now been visualised from the high-resolution structures of the 92 
tripartite efflux pumps that will be described later in this chapter.  93 
The periplasmic component of the tripartite architecture, the membrane fusion protein 94 
(MFP), bridges the IMP and the OMP. This protein class is characterised by defined domains 95 
identified by high resolution crystal structures, namely – the a-helical hairpin, lipoyl-like, b-96 
	 5 
barrel and membrane proximal domains (Figure 2A, C).  As we will describe below in detail, 97 
the MFP allosterically transduces conformational change from IMP to OMP. 98 
 99 
 100 
 101 
Fig. 2. A structural gallery of the AcrAB-TolC pump components and their domains. (A) 102 
Linear representation of the protein components of the AcrABZ-TolC system. (B-E) Protomer 103 
structures of the tripartite efflux pump components: TolC (B), AcrA Protomer-I and -II (C), 104 
AcrB (D), and AcrZ (E). TolC and AcrB form stable homotrimers in isolation, and both 105 
proteins have an internal structural repeat that arose from an ancestral gene duplication event. 106 
The figure was adapted from [31]. 107 
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 108 
Architecture of the tripartite pumps 109 
Combining the advances in electron cryo-microscopy (cryo-EM) with novel 110 
engineering approaches to stabilise the tripartite efflux pump assemblies, high-resolution 111 
structures have been attained for AcrAB-TolC [31, 32] and MacAB-TolC [33]. The cryo-EM 112 
structures of AcrAB-TolC reveal a trimer of TolC, a trimer of AcrB, and a hexamer of AcrA 113 
that bridges the two membrane protein components [31]. Some biochemical and genetic 114 
experiments indicate that only 3 molecules of AcrA (instead of 6) are sufficient for AcrAB-115 
TolC activity [34, 35], but this would not allow formation of a complex that is sealed so that 116 
substrates do not flow into the periplasm. The MacAB-TolC has a similar architecture to 117 
AcrAB-TolC, with a trimer of TolC and a hexamer of the periplasmic partner MacA; however, 118 
the inner membrane ATPase transporter MacB is a dimer [33, 36-39], in contrast to the trimeric 119 
AcrB transporter. For both systems, TolC interacts directly with the periplasmic partner (AcrA 120 
or MacA) in similar manner. On the other hand, there are no apparent similarities in the 121 
interactions of the trimeric AcrB with AcrA or the dimeric MacB with MacA. The atomic 122 
models of the AcrAB-TolC and MacAB-TolC tripartite assemblies are shown in Figure 3.  123 
 124 
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 125 
Fig. 3. Models of two tripartite assemblies, with speculation of the position of the 126 
peptidoglycan layer. (A) Structure of the RND-based AcrABZ-TolC (adapted after [31]), with 127 
a TolC trimer, an AcrA hexamer and AcrBZ trimer. (B) Structure the ABC-based MacAB-128 
TolC (adapted after [33]), with the TolC trimer, MacA hexamer and MacB dimer. TolC could 129 
potentially be anchored by an interaction between the equatorial domain and the peptidoglycan 130 
matrix in the periplasm. The speculation interaction of TolC with the peptidoglycan is based 131 
on the location of the layer based on tomographic reconstructions [40]. 132 
 133 
Although TolC and AcrB are both homo-trimers, the periplasmic partners MacA and 134 
AcrA are hexamers, and consequently the interactions between these proteins must involve a 135 
	 8 
loss of symmetry. The latter was evident from crystallographic data of AcrB captured with 136 
each of the three protomers in a different conformational state [41-43]. In fact, TolC and AcrB 137 
both bear a structural repeat and are therefore ‘honorary’ hexamers. Thus, the six interaction 138 
interfaces made between AcrA and either TolC or AcrB are approximately but not exactly 139 
equivalent. The same is true for the six interaction interfaces made between MacA and TolC. 140 
To distinguish these interfaces, the protomers in Figure 4A of AcrA are labelled as protomers 141 
I and II. The helix-turn-helix (HTH) elements at the periplasmic end of TolC interact in a tip-142 
to-tip fashion with the HTH units in the a-helical hairpin domains of AcrA [31] (i.e., six HTH 143 
units of the AcrA hexamer interact with 3 x 2 HTH units of the TolC trimer) (Fig. 4(B)). In 144 
detail, the AcrA protomer-I/TolC alignment involves residues K140 and S139 of AcrA and 145 
G365 of TolC [32] (Fig. 4(C)). Furthermore, L132 of AcrA is in direct contact with N145 and 146 
T366 of TolC [31].  147 
In the AcrAB-TolC pump, each of the three AcrA protomers-I aligns with the DN and 148 
DC subdomains of one AcrB protomer via its b-barrel domain, whereas its MP domain interacts 149 
with the PC1 subdomain, the PC2-DC linker-region, and a DN subdomain loop of a 150 
neighbouring AcrB protomer [31, 44] (Fig. 4(A)). AcrA protomer-II interacts with a b-hairpin 151 
of one AcrB protomer and a short a-helix of the DC subdomain of an adjacent AcrB protomer 152 
[31, 44] (Fig. 4(A)). The b-hairpin motif in the DN subdomain of AcrB was shown to be crucial 153 
for correct assembly of an active pump complex [45]. 154 
Both apo- and ligand-bound states of the AcrAB-TolC pump have been elucidated by 155 
cryo-EM [35]. In the apo-form state, the TolC trimer resembles the closed state seen in the 156 
crystal structure of the isolated protein, which has a constriction point where the coiled coils 157 
pinch together. In this closed state, inter-protomer hydrogen bonds are made between residue 158 
R367 of one protomer and T152, D153 and Y362 of an adjacent protomer [46-48]. However, 159 
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for the ligand-bound structures of the pump, TolC is in an open state. Comparing the open and 160 
closed forms suggests that TolC opens up in an iris-like dilation at its periplasmic end [31] 161 
through changes in the coiled coil geometry mediated through interaction with AcrA [49] (Fig. 162 
4(D)). In the MacAB-TolC assembly, the TolC is also in an open state. Six glutamine residues 163 
in the loops of MacA lipoyl domains form a uni-directional valve, which probably prevents 164 
back leakage of substrate into the periplasm during transport [33]. A direct interaction of 165 
substrate with the MFP may also occur for type-1 secretion systems [50]. 166 
 167 
 168 
Fig. 4. Overview of interactions between the AcrAB-TolC tripartite pump components. 169 
(A) Interaction of AcrA protomers I and II with subdomains PC1/2, PN1/2, and DC/DN of 170 
AcrB. (B) Cryo-EM map with fitted model shows the tip-to-tip interactions between AcrA and 171 
TolC in the resting state of the pump. (C) The tip-to-tip alignment of HTH motifs between 172 
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TolC and AcrA in the transport state. (D) The resting and transport state of TolC. Figure panels 173 
(A-D) adapted after [31].  174 
 175 
Conformational states and allosteric coupling in the AcrAB-TolC tripartite assembly 176 
Crystallographic data suggest that AcrB transitions through three distinct 177 
conformational states during the transport process, referred to as ‘loose’, ‘tight’, and ‘open’ 178 
(Fig 5) [31, 41-43]. In this mechanism, a substrate enters (‘Access’, or ‘L’ for loose) through a 179 
peripheral cleft and binds (‘Binding’, or ‘T’ for tight) to the drug-binding pocket of AcrB. The 180 
peripheral cleft closes up and a second pathway is opened (‘Extrusion’, or ‘O’ for open) 181 
towards the funnel in the docking domain of AcrB – through which the substrate eventually 182 
enters the AcrA-TolC ‘pipeline’ for extrusion to the cell’s exterior (Fig 5 A, B) [31, 41, 51].  183 
 184 
 185 
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Fig. 5. Cartoon schematic of the transport mechanism for AcrB. (A) The proposed ordered 186 
steps in binding of transport substrates (adapted after [52]). The orange circle represents the 187 
transport substrate, and the H+ is associated with titratable residues in the protein. (B) Energy 188 
transmission and upward movement of TM2 towards the AcrB periplasmic pore domain in 189 
response to protonation events in the trans-membrane domain for drug translocation [53, 190 
54]. 191 
 192 
Transport substrates enter the AcrB-protomers via the pore domain formed by the 193 
PN1/PN2 and PC1/PC2 subdomains (Fig. 4A and Fig. 2D) [29, 41]. The PN1/PN2 subdomains 194 
extend into the periplasm between TM1 and TM2, while PC1/PC2 are located between TM7 195 
and TM8 [29, 41]. All four subdomains together form an access (or proximal) pocket and a 196 
deep binding (or distal) pocket of an AcrB protomer [29, 41]. Differences between these two 197 
pockets in aromatic, charged, and polar residues are suggested to affect substrate preferences 198 
[55]. Water molecules have been found to additionally stabilize substrate binding [51, 56] 199 
inside the pocket and to contribute to drug binding and transport [57]. 200 
Substrates from the periplasm are thought to enter through a cleft formed by PC1/ PC2 201 
subdomains (Channel 1; Fig. 6) [51, 58]. Channel 1 seems to be present in both L and T 202 
protomers with the PC1/PC2 cleft being more closed in T. Substrates from the outer leaflet of 203 
the inner membrane are thought to gain access via two grooves formed between trans-204 
membrane helices 1 (TM1) and 2 (TM2) or TM7 and TM8, respectively (Channel 2; Fig. 6) 205 
[53]. High molecular weight macrolides (and maybe other substrates) are thought to enter via 206 
this channel. 207 
A third channel for drug entry (Fig. 6), with preference for planar, cationic aromatic 208 
compounds of low molecular mass (such as ethidium), has been hypothesised to take up 209 
substrate from a vestibule of an inner cavity formed between the three AcrB protomers [59]. 210 
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The third channel therefore by-passes the proximal binding pocket and the switch-loop that 211 
separates the two binding pockets (in red;) [59].  212 
There might be additional channels in AcrB given that carboxylated drugs (e.g. β-213 
lactams) were found to bind to the groove between TM1/TM2 [53].  One difficulty with these 214 
suggested binding sites is that they are relatively far from both binding pockets. However, a 215 
recently solved crystal structure of AcrB with fusidic acid bound in a cavity formed between 216 
TM1 and TM2 suggests that an upward movement of TM2 towards the AcrB periplasmic 217 
pore domain in response to protonation events in the transmembrane domain might help to 218 
translocate the drugs further into the assembly towards the AcrA-TolC tunnel [53] (Fig. 5B).  219 
 220 
 221 
Fig. 6. The three channels proposed for substrate entry in AcrB. Substrates can enter AcrB 222 
from the periplasm (Channel 1, purple) or from the outer leaflet of the inner membrane 223 
(Channel 2, green). Both lead via a proximal binding pocket (light blue) to a deep binding 224 
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pocket (pink). The third channel (Channel 3, yellow) is directly connected with the deep 225 
binding pocket and has its entrance from a central vestibule in a central cavity formed between 226 
the three AcrB protomers. It therefore by-passes the proximal binding pocket and switch-loop. 227 
All substrates leave the AcrB protomer via an exit channel (dark red). The latter leads to the 228 
funnel from which the substrate then passes through the AcrA-TolC tunnel with facilitation by 229 
water molecules [57]. 230 
 231 
Large conformational changes are observed in AcrB’s PN1/PC2 and PN2/PC1 modules 232 
during cycling through the L, T, and O states [51, 54], and the PN2/PC1 module opens and 233 
closes the deep binding pocket. The cycling through the three distinct conformational states 234 
appears to progress in a defined pattern, and the mechanism has accordingly often been referred 235 
to as “peristaltic” [42]. However, a recent investigation of crystal structures in combination 236 
with functional studies of the trimeric CemB, a AcrB homologue from the Gram-negative 237 
pathogen Campylobacter jejuni, suggests that CemB’s protomers perform conformational 238 
cycling independently from each other during the efflux process [60]. In the absence of a proton 239 
gradient, the protomers enter a symmetric resting state. It is not clear yet whether this model is 240 
distinct for a certain class of AcrB homologues, or applies more broadly and challenges the 241 
current model of ordered and coordinated transitions between distinct states.  242 
The cryo-EM data of AcrAB-TolC in the presence of puromycin identify different 243 
conformational states of AcrB in the full pump assembly which are consistent with the findings 244 
described above from X-ray crystallography [41, 42]. In the apo-state (resting state) of the 245 
pump, all three AcrB sub-units are in ‘loose’ conformation and TolC is in a closed state in 246 
which the channel is occluded for substrate exit. In this state, the AcrA subunits pack in manner 247 
that leaves gaps between the a-helical hairpin, lipoyl, and b-barrel domains. However, with 248 
transition to the ligand-bound form (transport state), the AcrA subunits re-pack to seal the gaps. 249 
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The configuration of the AcrA hexamer in the ligand-bound form opens the periplasmic end of 250 
TolC by tip-to-tip interactions of helical hairpins (Fig. 4(C, D)). The movement of AcrA that 251 
occurs with the apo- to ligand transition is inferred to originate from an energy-derived 252 
conformational switch in AcrB [31, 32]. A potential energy-conveying communication 253 
between the MFP and inner membrane components is also illustrated by the MacAB-TolC 254 
system, for which it was shown that MacA stimulates the ATPase activity of MacB [61].  The 255 
transition from resting to transport state of AcrAB-TolC is associated with a contraction of the 256 
pump along the long axis by ca. 10 Å. This contraction must result in a local compression of 257 
the periplasm to accommodate the axial contraction of the pump as well as a change in 258 
curvature of the outer and inner membrane near AcrB’s portal [31].  259 
 260 
Substrate interactions and substrate pathway 261 
Whereas substrate binding and the internal translocation mechanism is well explored 262 
for AcrB, for most other identified transporters it is not clear how the inner membrane 263 
component of the tripartite assembly interacts with the substrate. Three different entry routes 264 
of the substrate into the transporter are possible in principle: One from the inner or outer leaflet 265 
of the inner membrane, another from the cytoplasm, and the last from the periplasm. A 266 
substrate transported across the inner membrane into the periplasm by a ‘stand-alone’ 267 
transporter like MsbA may be picked up by a tripartite system and expelled across the outer 268 
membrane through the complex assembly. Indeed, there are dozens of different transport 269 
systems typically expressed simultaneously in a single bacterial cell, of which some work in a 270 
stand-alone manner as inner membrane transporters, and they can work in conjunction with 271 
tripartite assemblies as part of an efflux super-system [62-64] .  272 
The tripartite AcrAB-TolC system has been shown to transport chemically diverse 273 
substrates, including antibiotics like chloramphenicol, tetracycline, novobiocin, fusidic, 274 
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nalidixic acid, fluoroquinolones, various members of the b-lactam and macrolide antibiotic 275 
families [5, 6], as well as Triton X-100, bile salts, cationic dyes, disinfectants [7], nonpolar 276 
solvents [8, 9] and the mammalian steroid hormones estradiol and progesterone [65]. In the 277 
case of the E. coli MacAB-TolC system, transported substrates include macrolide [66], 278 
glycolipid [67], and lipopeptide [68], as well as the heat-stable enterotoxin II [69] which forms 279 
pores in mucosal cells of the intestinal wall. 280 
It is yet to be fully understood how the enormous poly-specificity of multidrug efflux 281 
tripartite assemblies arises. In part, the poly-specificity may arise from multiple binding sites 282 
residing within the same or different substrate binding pocket(s) [51, 58, 70, 71]. A puromycin-283 
bound AcrB structure provides an illustrating example for the complexity behind the significant 284 
poly-specificity observed in many transporters (Fig. 7). Some useful parallels may be drawn to 285 
QacR, a drug-binding regulator (repressor) of qacA (a MFS multidrug pump encoding gene 286 
from Staphylococcus aureus) [72, 73] for which multiple, linked drug-binding sites were 287 
identified [74]. For the mammalian ABC transporter ABCB1, data suggest the existence of 288 
multiple drug-binding pockets [75].  289 
 290 
 291 
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 292 
Fig. 7. Puromycin-bound AcrB structure. (A) The antibiotic is bound in the deep binding 293 
pocket of AcrB. (B) Schematic overview of main contacts between puromycin and AcrB. 294 
Figure adapted after [31] (PDB ID 5NC5).  295 
 296 
MacB and Type I Secretion System ABC transporters  297 
Tripartite efflux pump systems are closely related to the multi-component type I 298 
secretion machineries involved in the export of virulence proteins. For instance, the membrane 299 
fusion components share a similar binding motif for the outer membrane channel TolC [76]. 300 
The recently solved structures of the inner membrane ABC transporter component of a type I 301 
secretion system (Aquifex aeolicus AaPrtD, part of AaPrtDEF assembly) [77] and that of the 302 
ABC transporter MacB from the tripartite multi-drug efflux assembly MacAB-TolC [33, 37-303 
39] invite a structural comparison of these two systems. Both structures are depicted in Fig. 8. 304 
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 305 
Fig. 8. Structural comparison between two ABC transporter components of tripartite 306 
assemblies. (A) AaPrtD, the Aquifex aeolicus ABC transporter of the type 1 secretion system 307 
with close overall resemblance to many other solved ABC transporters (adapted after [77]). 308 
(B) MacB, the ABC transporter of the MacAB-TolC multi-drug efflux pump with its 309 
characteristic periplasmic domains (unique to all so far solved ABC transporters). The 310 
periplasmic domain forms extensive interactions with MacA in the tripartite assembly. The 311 
figure was adapted from [33].  312 
 313 
For most homo-dimeric ABC transporters, a transport model has been proposed 314 
according to which substrate engages a binding pocket in an inward-open state and is then 315 
expelled to the opposite site of the membrane when ATP-binding initiates a conformational 316 
change towards the outward-open state [78-85]. This alternating access model [80] is supported 317 
by observations from crystal structure of various ABC transporters that are captured in inward-318 
facing and outward-facing conformations [71, 79, 81, 82, 86-89]. The alternating access model 319 
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is summarised in Fig. 9(A)), depicting two identical protomers performing a clothes peg-like 320 
movement in a two-state cycle [85, 90]. According to this model, substrate enters the binding 321 
pocket(s) (several binding sites have been suggested for ABCB1, see [75, 91]) of the 322 
transporter in its inward-facing conformation. Substrate can access the transporter from the 323 
cytoplasm or the directly from the inner leaflet of the inner membrane (likely to be the case for 324 
hydrophobic substrates).  325 
The mechanism is depicted schematically in Fig. 9. A transporter with ATP bound to 326 
both nucleotide-binding domains (NBDs) undergoes conformational sampling, which enables 327 
NBD dimerization when a substrate binds [85]. An intermediate state occurs that has an 328 
occluded ATP in one nucleotide-binding site (NBS1) and a loose ATP in NBS2. The occluded 329 
ATP at NBS1 is hydrolysed to ADP-Pi whereas the loose ATP in NBS2 becomes occluded 330 
[85]. The hydrolysis of the occluded ATP in NBS2 to ADP-Pi drives a conformational switch 331 
to an outward-open conformation (like pressing the clothes pegs together); also, the inorganic 332 
phosphate dissociates from the ADP in NBS1 and the occluded ATP in NBS2 is hydrolysed to 333 
ADP-Pi [85]. In the outward-open conformation, substrate is released into the outer leaflet of 334 
the membrane [85].   335 
For hetero-dimeric ABC transporters, a constant-contact model (not displayed here) has 336 
been suggested, in which the NBDs never fully detach from each other [90, 92]. Here, substrate 337 
binds whilst one ATP molecule keeps the protomers together (i.e. catalytic asymmetry between 338 
NBDs) [90, 93-95]. A second ATP then binds and is hydrolysed – as a result of which 339 
protomers adapt another asymmetric state and substrate is released to the outside [90]. 340 
Following substrate release and the dissociation of phosphate, the protomers re-adapt the apo-341 
state with one ATP molecule still holding both halves together [90]. The release of ADP 342 
enables re-binding of substrate [90].  343 
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It is therefore plausible that homo-dimeric transporters also cycle through step-wise 344 
ATPase stages, instead of both ATP molecules being hydrolysed simultaneously. Interestingly, 345 
a constant-contact with catalytic asymmetry has also been suggested for the mammalian homo-346 
dimeric ABC transporter P-glycoprotein [96-98].  347 
 348 
 349 
Fig. 9. Alternating access model for ABC transporter. Blue figures, two half-transporters; 350 
purple circles, ATP; purple circles with black borders, ADP; purple circles with black borders 351 
and black central dot, ADP-Pi; orange hexagon, drug/substrate. In the outward-open (pressed 352 
drying clothes peg-like) conformations, the trans-membrane domains of the transporters are 353 
opened up towards the external side of the membrane. Each depicted domain wing contains 354 
two trans-membrane helices: From one trans-membrane domain and four trans-membrane 355 
helices from the other half. Model adapted after [85]. 356 
           357 
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Like MacB, the Aquifex aeolicus PrtD protein (aaPrtD) forms a homo-dimer (Figure 8). 358 
aaPrtD is the energy transducing component of a tripartite Type I secretion system that includes 359 
the MFP PrtE, and the OMP PrtF. Type I secretion complexes transport virulence factors, 360 
including ligases, scavenging molecules, and proteases [99-102]. These transport substrates 361 
must be in an unfolded state in order to be transported [103, 104]. Interestingly, with some of 362 
these substrates exceeding 8,000 amino acids [99, 101], these lengthy unfolded polypeptide 363 
chains are assumed to move continuously through a pore formed by the transmembrane 364 
domains [105, 106]. A well-studied Type I section system is the HlyDB-TolC complex that 365 
transports hemolysin A (HlyA), for which experimental evidence indicates transport occurs 366 
directly from the cytosol without a periplasmic intermediate [99, 107-109].  In the case of PrtD, 367 
a basal ATPase activity may be repressed by substrate binding, which could prevent the closure 368 
of nucleotide-binding domains. In this state, PrtD binds the other components PrtE and PrtF 369 
[77, 110-112]. The full assembly is suggested to reactivate PrtD’s ATPase activity and 370 
therewith to enable the substrate transport [77, 113, 114]. A potentially related stimulation by 371 
the MFP has previously been demonstrated for the interaction of MacA with MacB [61]. How 372 
ABC transporters like PrtD transport peptides requires further characterization. 373 
Although MacB was originally described as a macrolide efflux inner membrane 374 
transporter as part of the MacAB-TolC tripartite system, it has been shown to also transport a 375 
71 amino-acid long heat-stable enterotoxin II (STb-II) [69]. Unlike the Type I secretion system, 376 
the peptide substrate appears to be taken up by the MacAB-TolC tripartite machinery from the 377 
periplasm rather than the cytoplasm, since the STb-II is translocated via the Sec system into 378 
the periplasm where it is processed [115-117]. This periplasmic entry could hint towards an 379 
alternative transport mechanism to those observed for other ABC transporters so far.  In this 380 
model, substrate enters MacB via the periplasm and binds to a disclosed binding cavity in the 381 
outward-open MacB-dimer, while ATP hydrolysis and release of inorganic phosphate might 382 
	 21 
then trigger the release of substrate with subsequent passage through MacA into the MacA-383 
TolC part of the extrusion machinery. This resembles more closely the outward-only model as 384 
distinct from the alternating access model.  385 
In comparison to AaPrtD and all other structurally characterised ABC transporters, 386 
MacB has extensive periplasmic domains. The MacB periplasmic domains form interactions 387 
with MacA, and since these are not present in AaPrtD, the Type I secretion systems must have 388 
a different organization for the interactions between the ABC and MFP components.  MacB 389 
reveals the characteristic ‘anchoring’ helices at the inner leaflet-cytosol interface [33, 37-39] 390 
which so far have been observed in an ABCG5/8 type-II exporter structure [118]. MacB 391 
furthermore shows closer proximity of nucleotide-binding domains to the inner leaflet, as 392 
opposed to the larger extensions of trans-membrane (TM) helices into the cytosol in other ABC 393 
transporters. MacB’s 4 trans-membrane helices lack the characteristic kinks seen in AaPrtD’s 394 
TM3 and TM6 [77], and the 4 TMs are the smallest observed number amongst ABC 395 
transporters with known structures [119]. AaPrtD utilises both pairs of its 6-bundled TMs to 396 
form a continuous channel for unfolded substrate transport across the inner membrane, which 397 
in the resolved ADP-bound occluded structure was closed at the cytosolic side via a conserved 398 
Arginine on TM6 between TM6 and TM4, and on the periplasmic side via a pore ring 399 
consisting of hydrophobic residues [77]. The latter is unique amongst known transporters and 400 
may prevent leakage of protons along the gradient [77].  401 
 The location of the substrate binding site(s) is unknown for both transporters. For 402 
AaPrtD, substrate interaction at the concave surface and near the cytosolic window where TM4 403 
separates from TM6 have been suggested [77] based on previous studies [105, 120-123]. For 404 
MacB, an unidentified density, occluding the region between the periplasmic extensions of 405 
TM1 and TM2, might hint towards a putative substrate interaction or binding site [33]. 406 
 407 
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Tripartite pump regulation 408 
Analyses of overexpressed tripartite pumps involved in the efflux of multiple antibiotic 409 
compounds in clinical isolates [124, 125] demonstrate the importance of pump regulation for 410 
drug design applications and clinical practice. Tripartite pump expression levels can be 411 
regulated by two component systems comprised of a sensor histidine kinase and a response 412 
regulator (the mechanisms of two component systems are reviewed in [126-128] inter alia). 413 
Mutations in these systems have been identified in numerous clinical isolates [129] and were 414 
shown to contribute to pump overexpression [129-131]. In brief, first a histidine kinase senses 415 
environmental signals like the presence of toxic compounds (e.g. antibiotics). The ‘sensing’ 416 
usually happens indirectly though cases of direct sensing are known: The Streptomyces 417 
coelicolor VanS (VanSsc) histidine kinase was shown to directly bind vancomycin [132]. 418 
Interestingly, in the case of bacitracin resistance in Bacillus subtilis, the bacitracin transporting 419 
ABC transporter BceAB acts as a sensor itself by mediating information on its transport 420 
activity, though protein-protein interaction, to the histidine kinase BceS [133]. Other examples 421 
for two component systems that regulate efflux pump expression include AmgRS in 422 
Pseudomonas aeruginosa, CpxAR in Enterobacteriaceae, and AdeSR in Acinetobacter 423 
baumannii [134]. In the latter case, AdeR (the response regulator) activates the expression of 424 
the adeABC tripartite system genes by binding to a direct-repeat motif in the intercistronic 425 
spacer [135]. Interestingly, at least some two component systems seem to be capable of multi-426 
system regulation: The BaeSR system in Salmonella typhimurium, for instance, has been 427 
shown to regulate both acrD and mdtABC expression [136]. The same system in E. coli 428 
activates both of the latter in response to the presence of indole [137].  429 
Further along the signal transduction cascade, local and global regulators fine-tune 430 
tripartite system expression levels. For instance, transcription of acrAB, encoding AcrA and 431 
AcrB is controlled by local repressors like AcrR [138], global regulators like MarA, SoxS, 432 
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and Rob [139], as well as global expression activators like RamA [140, 141] (with its 433 
repressor protein RamR [142], whose RamA-repressing activity in turn is downregulated 434 
via drug binding [143]). Other local repressors like TetR/QacR family members (e.g. emrR, 435 
acrR, mtrR) downregulate pump expression [144-147]. These control elements reveal a rather 436 
complex regulatory network for fine-tuned expression. Overexpression of AraC/XylS global 437 
regulator family members (e.g. MarA, SoxS, and Rob) has been shown to result in pump 438 
overexpression and consequently increased efflux activity [148]. These regulators can be 439 
induced by substrates of the pump systems they are regulating. In Pseudomonas aeruginosa, 440 
for example, the mexZ gene encodes a putative repressor of the mexYX operon (part of the 441 
MexXY-OprM tripartite system). In a mexZ-defective mutant, the mexY gene was found to be 442 
induced by various ribosome inhibitors like macrolides and chloramphenicol, but not by 443 
antibiotics acting on other cellular targets [149]. Such a complex regulatory pattern hints 444 
towards an additional physiological role for the Mex system beyond antibiotic efflux, and 445 
suggests that there are additional regulatory loci for mexYX [149]. Surprisingly, for the MexEF-446 
OprN tripartite pump in P. aeruginosa, toxic electrophiles were recently identified to induce 447 
expression through the transcriptional regulator CmrA [150].  448 
Regulation of different pump systems was also shown to be cross-linked in some cases: 449 
Deactivation of acr genes leads to an up-regulation of other efflux pump systems [151]. 450 
Furthermore, when AcrAB pump activity is impaired, AcrEF has been found to be 451 
upregulated in the presence of quinolones [152] and overexpressed AcrD replaces AcrB to 452 
form a tripartite assembly with AcrA-TolC (however, this replacement is repressed by AcrB-453 
specific substrates) [153]. These examples show how well the efflux pump part of the 454 
bacterial proteome is coordinated and adjustable to compensate for loss of any component.  455 
Regulation can furthermore happen on the post-transcriptional level. Both transcription 456 
and translation attenuation can be abrogated by direct interaction of antibiotics with the 457 
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ribosome during translation upstream of resistance gene(s). The ribosome is temporarily stalled 458 
so that an RNA secondary structure can form which (1) exposes the ribosome-binding site for 459 
translation or (2) allows for the formation of an antiterminator structure, which enables the 460 
RNA-polymerase to continue with transcription beyond a terminator [154]. As a consequence, 461 
the resistance gene(s) can be translated or transcribed, respectively.  462 
Other examples of post-transcriptional regulation involve sRNAs like SdsR. The latter 463 
binds and thereby represses tolC mRNA in E. coli and Salmonella [155]. Other examples 464 
include MdtEF regulation by DsrA in E. coli [156] and MtrF (part of MtrCDE) regulation by 465 
NrrF in Neisseria gonorrhoeae [157]. Furthermore, sRNAs can ‘re-wire’ two component 466 
cascades and therewith indirectly influence expression level [158].  467 
It has widely been assumed that an overexpression of pumps would impact on the cell. 468 
For instance, overexpression of AcrAB in Salmonella typhimurium was suggested to come at 469 
the expense of fitness and virulence [159]. Overexpression of AcrB also resulted in a switch in 470 
E. coli’s carbon metabolism from a respiratory to fermentative mode [160]. In contrast to these 471 
findings, overexpression of AcrAB in a RamR-deletion mutant of Klebsiella pneumoniae 472 
revealed increased virulence [161] and overexpression of MtrCDE in Neisseria gonorrhoeae 473 
increased fitness [162]. Furthermore, studies in Pseudomonas aeruginosa have shown that the 474 
overexpression of the MexEF-OprN tripartite efflux pump system does not necessarily 475 
decrease fitness – perhaps due to increased expression of genes encoding the nitrate respiratory 476 
chain that might boost metabolic energy [163]. The increased presence of pumps in the 477 
membrane may disturb pH homeostasis, which might be compensated by upregulated aerobic 478 
respiration. This might account for the finding that, in an anaerobic environment, an increased 479 
intracellular pH was measured in the over-expressing cells.  480 
In addition to pump overexpression, mutants can account for increased pump activity: 481 
A G288D substitution in AcrB’s binding pocket changed the substrate specificity of the pump, 482 
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conferring ciprofloxacin resistance [164]. Mutations in binding pockets have also been 483 
identified in clinical isolates [165]. 484 
Regulation can furthermore happen on the post-translational level. The activity of the 485 
AcrAB-TolC pump for instance can be modulated by allosteric ligands. This is evident in the 486 
increased resistance for some but not all of AcrB’s substrates through the binding of a 49 487 
amino-acid long alpha-helical protein described as AcrZ [166]. AcrZ expression is co-regulated 488 
with AcrB by MarA, Rob, and SoxS [166]. The small protein binds to a groove in the inner 489 
membrane-facing site of AcrB [166]. The exact mechanism by which AcrZ increases resistance 490 
to tetracycline, puromycin and chloramphenicol remains to be explored.  491 
 Little is known about factors and conditions affecting pump assembly and disassembly. 492 
The fact that outer membrane channels like TolC are used by multiple systems suggests 493 
however that pump complexes assemble and disassemble in a transient fashion. Corresponding 494 
findings from literature so far hint towards a regulatory role of the proton-motive-force for 495 
pump disassembly (but not assembly). In particular, for the Neisseria MtrCDE system it was 496 
found that whereas opening of the outer-membrane channel (MtrE) via interaction with the 497 
membrane-fusion protein (MtrC) is energy-independent, drug export and complex dissociation 498 
are dependent on active proton transport [167]. Studies of influx/efflux patterns by single 499 
transporters in de-energised cells have demonstrated drug uptake driven by the drug gradient 500 
in exchange for the export of protons (e.g. utilised in [168]). In order to counteract drug uptake 501 
by the same system, pump complex disassembly and associated closure of the outer membrane 502 
channel are needed. This could be related to the recently revealed 'twist-to-open' mechanism 503 
mediated by the tip-to-tip interaction of TolC and AcrA [31] as well as with the observations 504 
of rapid MexAB-OprM disassembly upon reaching thermodynamic equilibrium [169]. 505 
Interestingly however, experiments with a MexB mutant with a disrupted proton relay network 506 
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indicate that the assembly is still stable despite its inability to transport substrate [169, 170]. In 507 
ABC transporters, it remains completely unclear how pump (dis-)assembly is governed.  508 
 Two possible regulatory mechanism of pump assembly and disassembly have been 509 
suggested for the AcrAB/TolC system[171].  In one scenario, a drop in the periplasmic drug 510 
concentration triggers the AcrB-trimer to acquire its pure LLL state, which lowers AcrA's 511 
affinity for the AcrB trimer and henceforth shifts the equilibrium towards pump disassembly. 512 
In a second scenario, tripartite (dis-)assembly could be pH-dependent given that the AcrAB 513 
complex formation itself is favoured at a periplasmic pH of 6.0 but not at pH 7.5 [172]. 514 
Elevated periplasmic pH levels are indicative of a decreased proton-motive-force. A complex 515 
disassembly at elevated pH/lowered pmf levels might therefore prevent the possibility of drug 516 
uptake via the tripartite assembly itself. This might explain why the transport activity of the 517 
AcrAB/TolC synchronises with fluctuation of pmf levels in the cell (high activity at high pmf 518 
levels) [173-175].  519 
  520 
Summary and perspective 521 
The cell envelope of Gram-negative bacteria is a formidable barrier to the movement 522 
of materials, and dedicated machinery is required to translocate substances including nutrients, 523 
virulence factors and antibiotics through the cell envelope. The efflux of drugs and other 524 
bactericidal compounds is achieved through tripartite nano-machines that transduce energy 525 
derived from electrochemical transmembrane gradients or ATP hydrolysis to drive the efflux 526 
process. The architecture of representative assemblies reveals common features for the RND 527 
and ABC powered systems, and the mechanism of action involves a high degree of cooperation 528 
between the protomers of the assembly.  529 
Current understanding of the transport process by tripartite assemblies envisages that 530 
the inner membrane component, sourcing energy for transport from either ATP hydrolysis 531 
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(ABC transporter) or electro-chemical gradients across the inner membrane, recognises and 532 
binds substrates and guides these into the tripartite assembly for extrusion outside of the cell. 533 
Depending on the system, the transporters reveal different degrees of poly-specificity, with 534 
some recognising hundreds of chemically unrelated molecules (small compounds to medium-535 
sized peptides) whilst others are specialised in the transport of selected ions. Poly-specificity 536 
is the result of multiple binding sites and of a variety of residues acting as potential binding 537 
partners. The transport through the outer membrane is typically conducted via a channel protein 538 
(e.g. TolC). The latter is ‘opened’ up for substrate-transport via the interaction with the 539 
membrane fusion protein, which establishes the connection between the two separated 540 
membrane components and transduces energy from the inner membrane component for 541 
conformational changes in the entire tripartite system, including the opening of the outer 542 
membrane channel.  543 
One area of considerable interest with view to pump activity is the exploration of 544 
specific locations of efflux pump assemblies within the membrane system. For the E. coli 545 
AcrAB-TolC system, it has been shown that the older and more drug resistant mother cells 546 
accumulate the pump assembly in clusters at the cell poles [176]. In relation with this 547 
observation, lipid rafts might play a putative role in pump-activity and/or -specificity 548 
regulation. Lipids can stabilise membrane protein oligomer formation [177] and also 549 
facilitate large conformational changes within membrane proteins [178]. The role of lipids 550 
for pump localization and regulation is an important topic for future investigations [179]. 551 
High-resolution structures have often been the starting point for functional exploration 552 
towards a better and more detailed understanding of efflux mechanisms. Such understanding 553 
can be the basis for inhibitor design (e.g. the pyranopyridine derivatives MBX2319, MBX2931, 554 
MBX3132, and MBX3135 as AcrB inhibitors) [56, 180]. Pump inhibitors could be used as 555 
novel antibiotic agents in the fight against multiple antibiotic resistance as well as for studies 556 
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towards a better structural and functional characterization of pumps in general. With the recent 557 
emergence of high resolution structures of tripartite pumps, interesting functional findings can 558 
be expected in the near future. 559 
There are numerous important puzzle regarding efflux mechanisms. How much energy 560 
is required for efflux, and how efficient is the process? Could some of the energy used to 561 
discriminate transport substrates in a process that is analogous to kinetic proofreading? 562 
Addressing these questions demands in vitro techniques with reconstituted purified protein in 563 
liposomes, as established mostly for Gram-positive transporters in the past. These have been 564 
challenging with tripartite system due to their assembly in double-membrane system [61]. A 565 
successful functional reconstitution of a tripartite system has been achieved for the MexAB-566 
OprM system in liposomes so far and was utilised for in vitro activity studies [169]. 567 
Furthermore, the recently described reconstitution technique using lipid nanodiscs [181-183] 568 
have opened new possibilities for both structural and functional analyses of membrane 569 
proteins. Tripartite systems reveal a complex pattern of pre- and post-translational regulation 570 
in response to the environment and physiological needs of the cell. An understanding of the 571 
tripartite proteome-regulatory network as well as of the expression-induced effects on bacterial 572 
physiology are needed in order to design effective drugs against tripartite assemblies. There is 573 
still much to learn about how these systems are regulated, their functions, and their highly 574 
cooperative mechanisms. 575 
 576 
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